Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4579)
All Articles published online
|
Publishing Process of This Article
|
Jul 21, 2021 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hamad A, Brown ZJ, Ejaz AM, Dillhoff M, Cloyd JM. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. World J Gastroenterol 2021; 27(27): 4383-4394 [PMID: 34366611 DOI: 10.3748/wjg.v27.i27.4383] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v27/i27/4383.htm |
| Number | Citing Articles |
| 1 |
Anne Claire Henry, Thijs J. Schouten, Lois A. Daamen, Marieke S. Walma, Peter Noordzij, Geert A. Cirkel, Maartje Los, Marc G. Besselink, Olivier R. Busch, Bert A. Bonsing, Koop Bosscha, Ronald M. van Dam, Sebastiaan Festen, Bas Groot Koerkamp, Erwin van der Harst, Ignace H. J. T. de Hingh, Geert Kazemier, Mike S. Liem, Vincent E. de Meijer, Vincent B. Nieuwenhuijs, Daphne Roos, Jennifer M. J. Schreinemakers, Martijn W. J. Stommel, I. Quintus Molenaar, Hjalmar C. van Santvoort. Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis. Annals of Surgical Oncology 2022; 29(9): 6031 doi: 10.1245/s10434-022-11831-7
|
| 2 |
Zachary J Brown, Victor Heh, Hanna E Labiner, Guy N Brock, Aslam Ejaz, Mary Dillhoff, Allan Tsung, Timothy M Pawlik, Jordan M Cloyd. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. British Journal of Surgery 2022; 110(1): 34 doi: 10.1093/bjs/znac354
|
| 3 |
Heng‐Chung Kung, Jun Yu. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. MedComm 2023; 4(2) doi: 10.1002/mco2.216
|
| 4 |
Bohan Yang, Kai Chen, Weikang Liu, Di Long, Yingjin Wang, Xinxin Liu, Yongsu Ma, Xiaodong Tian, Yinmo Yang. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis. Clinical and Experimental Medicine 2023; 23(7): 3159 doi: 10.1007/s10238-023-01112-2
|
| 5 |
Valeria Merz, Domenico Mangiameli, Camilla Zecchetto, Alberto Quinzii, Silvia Pietrobono, Carlo Messina, Simona Casalino, Marina Gaule, Camilla Pesoni, Pasquale Vitale, Chiara Trentin, Michela Frisinghelli, Orazio Caffo, Davide Melisi. Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. Frontiers in Surgery 2022; 9 doi: 10.3389/fsurg.2022.866173
|
| 6 |
Zachary J. Brown, Samantha M. Ruff, Jordan M. Cloyd. Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence. Current Opinion in Pharmacology 2022; 67: 102305 doi: 10.1016/j.coph.2022.102305
|
| 7 |
Dong-Qin Xia, Yong Zhou, Shuang Yang, Fang-Fei Li, Li-Ya Tian, Yan-Hua Li, Hai-Yan Xu, Cai-Zhi Xiao, Wei Wang. Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma. World Journal of Gastrointestinal Oncology 2024; 16(3): 798-809 doi: 10.4251/wjgo.v16.i3.798
Abstract(75) |
Core Tip(84) |
Full Article(HTML)(607)
|
Full Article with Cover (PDF)-2130K(15)
|
Full Article (Word)-886K(0)
|
Audio-236K(0)
|
Peer-Review Report-261K(9)
|
Answering Reviewers-163K(10)
|
Full Article (PDF)-1863K(24)
|
Full Article (XML)-126K(11)
|
Times Cited (0)
|
Total Visits (1233)
|
Open
|
| 8 |
Zhiqi Zhang, Haitao Yu, Wenyan Yao, Na Zhu, Ran Miao, Zhiquan Liu, Xuwei Song, Chunhua Xue, Cheng Cai, Ming Cheng, Ke Lin, Dachuan Qi. RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway. Cell Communication and Signaling 2022; 20(1) doi: 10.1186/s12964-022-00974-5
|